Rein Therapeutics receives orphan drug designation from EMA for LTI-03

Rein Therapeutics (RNTX) announced that it has received orphan drug designation from the European Medicines Agency, EMA, for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis, IPF. The designation follows a positive opinion from the EMA’s Committee for Orphan Medicinal Products, COMP, and subsequent adoption by the European Commission.